Daily Cosmetic Research Analysis
Analyzed 18 papers and selected 3 impactful papers.
Summary
A randomized split-tattoo trial shows 755-nm picosecond alexandrite lasers outperform nanosecond devices for tattoo removal with higher clearance, less pain, and fewer acute complications but more hyperpigmentation. A PRISMA-guided meta-analysis indicates amino acid–enriched hyaluronic acid improves wrinkles and dermal thickness with acceptable safety. A multicenter retrospective study supports the feasibility and cosmetic advantages of single-port robot-assisted nipple-sparing mastectomy with low complication rates.
Research Themes
- Laser-based aesthetic treatments and safety trade-offs
- Injectable biostimulatory formulations for facial rejuvenation
- Minimally invasive oncologic surgery with cosmetic preservation
Selected Articles
1. 755-nm Picosecond vs. Nanosecond Alexandrite Lasers for Tattoo Removal: A Randomized, Split-Tattoo Clinical Trial.
In a randomized split-tattoo trial (n=30), 755-nm picosecond alexandrite laser achieved superior clearance versus nanosecond with higher rates of satisfactory and complete clearance, lower pain, and fewer acute complications, albeit with increased hyperpigmentation. Findings support PSAL as a first-line modality for black/blue tattoos, with parameter optimization to mitigate pigmentary risk.
Impact: Provides high-level, randomized evidence directly comparing picosecond and nanosecond alexandrite lasers for tattoo removal with clinically meaningful endpoints and safety data.
Clinical Implications: Prefer 755-nm PSAL for black/blue tattoo removal to achieve higher clearance with less pain and fewer acute reactions; counsel patients on higher hyperpigmentation risk and tailor pulse parameters and intervals, especially in darker skin types.
Key Findings
- Higher clearance with PSAL vs NSAL (VAS median 8 [IQR 6–9] vs 5 [2.75–6.25]; p<0.0001).
- Satisfactory clearance (VAS ≥7) in 73.3% with PSAL vs 23.3% with NSAL (p=0.0003); complete clearance 10% vs 0%.
- Lower pain with PSAL (p=0.023) and fewer acute events: bleeding 2% vs 8% (p=0.031), blistering 7.33% vs 15.33% (p=0.044), crusting 7.33% vs 15.33% (p=0.044).
- Higher hyperpigmentation with PSAL (21.33% vs 12%; p=0.043).
Methodological Strengths
- Prospective, randomized, split-tattoo design with within-subject control reduces inter-tattoo variability.
- Registered trial with standardized outcomes and predefined follow-up.
Limitations
- Modest sample size (n=30) and 6-month follow-up limit long-term generalizability.
- Restricted to black/blue tattoos; pigmentation sequelae higher with PSAL.
Future Directions: Evaluate longer-term recurrence/clearance, optimize pulse parameters to reduce hyperpigmentation, and extend to multicolor tattoos and diverse Fitzpatrick skin types.
BACKGROUND: Tattoo removal has advanced with the introduction of picosecond laser technology, offering theoretical advantages over traditional nanosecond approaches. However, high-level clinical evidence comparing these modalities utilizing 755-nm alexandrite lasers is lacking. METHODS: A prospective, randomized, split-tattoo trial was performed in 30 subjects with professional (53.3%), amateur (33.3%), or cosmetic (13.3%) black/blue tattoos. Each tattoo was divided, with one half treated using a 755-nm picosecond alexandrite laser (PSAL) and the other with a nanosecond alexandrite laser (NSAL). Treatments were performed at 3-month intervals for five sessions, with 6-month follow-up. The primary outcome was clearance score on a 10-point visual analogue scale (VAS). Secondary endpoints included proportion achieving satisfactory clearance (VAS ≥7), pain, and adverse events. RESULTS: PSAL achieved higher clearance scores versus NSAL (8, IQR: 6-9 vs. 5, IQR: 2.75-6.25; p < 0.0001) and greater rates of satisfactory clearance (73.3% vs. 23.3%; p = 0.0003). Complete clearance occurred in 10% of PSAL-treated sites versus none with NSAL. Pain scores were lower with PSAL (5, IQR: 3-6 vs. 5, IQR: 3-7, p = 0.023). Acute complication rates were reduced in PSAL versus NSAL: bleeding (2% vs. 8%, p = 0.031), blistering (7.33% vs. 15.33%, p = 0.044), and crusting (7.33% vs. 15.33%, p = 0.044), but hyperpigmentation occurred more frequently (21.33% vs. 12%; p = 0.043). CONCLUSIONS: The 755-nm PSAL significantly outperforms NSAL for tattoo removal. Optimization of pulse parameters may further improve outcomes and minimize pigmentary sequelae.Trial Registration: Chinese Clinical Trial Registry (https://www.chictr.org.cn/) identifier: ChiCTR2300069281.
2. Efficacy and Safety of Amino Acid-Enriched Hyaluronic Acid in Facial Rejuvenation: A Systematic Review and Meta-Analysis.
This PRISMA-guided meta-analysis of 11 studies suggests that amino acid–enriched hyaluronic acid reduces wrinkle severity, increases dermal thickness, and improves EGF-positive cell viability, with acceptable safety and patient-reported aesthetic gains. Heterogeneity and short follow-up temper certainty but support clinical consideration in facial rejuvenation.
Impact: Synthesizes multi-domain outcomes (clinical scales, imaging/histology, and safety) to appraise a widely used injectable formulation, informing evidence-based aesthetic practice.
Clinical Implications: Consider HA+AA formulations for patients seeking skin quality improvement beyond volumization, with counseling on expected benefits and the need for maintenance; standardize outcome measures and monitor adverse events.
Key Findings
- Wrinkle Severity Rating Scale improved (MD 2.15; 95% CI 2.00–2.30; p<0.0001).
- Global Aesthetic Improvement Scale showed marked gains at 3 months (MD 3.13; 95% CI 1.94–4.33; p<0.00001).
- Post-treatment dermal thickness increased and EGF-positive cell viability improved significantly.
- Adverse events were not significantly different versus comparators (RR 5.20; 95% CI 0.53–50.77; p=0.16), though precision was limited.
Methodological Strengths
- PRISMA-guided systematic search across multiple databases with comparator-controlled studies.
- Quantitative synthesis encompassing clinical scales, dermal metrics, and cellular markers.
Limitations
- Heterogeneous protocols and outcome measures; some effect direction reporting inconsistencies.
- Short follow-up in most studies; limited sample sizes and unclear publication bias assessment.
Future Directions: Conduct larger, blinded RCTs with standardized endpoints, longer-term durability and safety assessment, and head-to-head comparisons with conventional HA and energy-based devices.
INTRODUCTION: Skin aging, marked by wrinkles, volume loss, and reduced hydration, has driven growing interest in minimally invasive aesthetic treatments to restore skin quality and appearance. This study aimed to evaluate the efficacy and safety of an injectable formulation combining hyaluronic acid (HA) and amino acids (AA) for facial rejuvenation in adults. METHODS: A systematic review and meta-analysis was conducted according to the PRISMA guidelines using PubMed, EMBASE, Scopus, and the Cochrane Library. Eligible studies compared HA + AA complexes with conventional HA or a placebo. The primary efficacy outcomes were changes in wrinkle severity (WSRS), aesthetic improvement (GAIS), skin thickness, and epidermal growth factor (EGF)-positive cell viability. Safety was assessed by adverse event reporting. RESULTS: This meta-analysis included 11 studies that met the inclusion criteria. A significant reduction in wrinkle severity was observed on WSRS following treatment (MD, 2.15; 95% CI, 2.00-2.30; p < 0.0001). Global aesthetic improvement demonstrated a marked enhancement at 3 months (MD = 3.13; 95% CI = 1.94-4.33; p < 0.00001). Dermal thickness significantly increased post-treatment (MD = -0.42 mm; 95% CI = -0.55 to -0.30; p < 0.00001). Cell viability improved significantly (MD = -24.00; 95% CI = -25.16 to -22.84; p < 0.00001). There was a statistically significant difference in adverse events (RR = 5.20; 95% CI = 0.53-50.77; p = 0.16). CONCLUSION: Amino acid-enriched hyaluronic acid improves wrinkle severity, dermal thickness, and cell viability, enhancing overall skin aesthetics. Larger prospective studies are needed to confirm these findings.
3. Single-Port Robot-Assisted Nipple-Sparing Mastectomy: Main Analysis of a Retrospective Multicenter Study (SPROUT, KoREa-BSG 09).
In 428 patients across 12 centers, single-port robotic nipple-sparing mastectomy showed feasibility and safety, with 80% complication-free recovery, seroma as the most common event (10.5%), and a 2.8% reoperation rate. Operative time was influenced by breast weight, nodal status, and tumescent use; no clear learning-curve shortening was observed.
Impact: Provides large multicenter data supporting minimally invasive, cosmetically favorable oncologic breast surgery using single-port robotics, informing resource planning and patient selection.
Clinical Implications: SP-RNSM can be considered in centers with robotic expertise, with attention to patient factors (e.g., breast weight, nodal status) that prolong operative time; strategies like tumescent solution may improve efficiency while preserving cosmetic outcomes.
Key Findings
- Multicenter cohort of 428 SP-RNSM cases with 80% complication-free recovery; seroma 10.5%, reoperation 2.8%.
- Total operative time averaged 333.5 ± 132.6 minutes; breast surgeon time associated with breast weight, nodal metastasis, and not using tumescent solution.
- No consistent learning curve reduction in operative time despite increasing case volume.
Methodological Strengths
- Large multicenter dataset spanning 12 institutions, enhancing external validity.
- Multivariable analysis to identify predictors of operative efficiency and a formal learning-curve assessment.
Limitations
- Retrospective design without a control group limits causal inference and comparative effectiveness.
- Oncologic long-term outcomes and patient-reported cosmetic/quality-of-life measures were not detailed.
Future Directions: Prospective comparative trials versus open/multi-port approaches, standardized cosmetic and quality-of-life endpoints, and cost-effectiveness analyses are warranted.
BACKGROUND: The emergence of single-port robotic systems has enabled their application in breast surgery, offering minimally invasive, cosmetically favorable options for mastectomy. This study aimed to evaluate surgical outcomes and operative efficiency of single-port robotic-assisted nipple-sparing mastectomy (SP-RNSM) across multiple institutions in Korea based on early experiences. METHODS: This multicenter retrospective study included the patients with primary breast cancer who underwent SP-RNSM with or without axillary surgery and immediate reconstruction between January 2018 and November 2023 at 12 institutions in Korea. Clinicopathologic characteristics, operative variables, including operative time, and postoperative outcomes were collected. RESULTS: A total of 428 patients were included in this study. Among them, 81.5% were diagnosed with invasive carcinoma, and 18.5% with ductal carcinoma in situ. The mean age was 45.7 years, and 78.5% were premenopausal. Direct-to-implant was the most common reconstruction method (66.1%). The mean breast surgeon's operative time, plastic surgeon's operative time, and total operative time were 160.5 ± 54.1, 167.1 ± 116.1, and 333.5 ± 132.6 minutes. Multivariable analysis identified lymph node metastasis, heavier breast weight, and absence of tumescent solution use as independent predictors of longer BS time, with breast weight showing the strongest association. Postoperatively, 80% of patients recovered without complications. The most common complication was seroma (10.5%), and the reoperation rate was 2.8%. In the learning curve analysis, no consistent or marked decrease in operative time was observed with increasing case numbers. CONCLUSIONS: The SP-RNSM is a feasible and safe approach for breast cancer surgery with favorable surgical outcomes and minimal complications.